Imunon Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
IMNN$0.88+4.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity
YEAR ENDED DECEMBER 31, 2024
| Common Stock Outstanding · Additional Paid-in · Treasury Stock · Accum. Other Compr. Income · Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount · Capital · Shares · Amount · (Loss) · Deficit · Total | |||||||||
| Balance at January 1, 2024 | 9,399,811 | $93,998 | $401,500,838 | 22 | $(85,188) | $60,796 | $(388,182,802) | $13,387,642 | |
| Net loss | - | - | - | - | - | - | (18,620,242) | (18,620,242) | |
| Sale of equity through equity financing facilities | 5,088,796 | 50,888 | 9,009,550 | - | - | - | - | 9,060,438 | |
| Issuance of stock upon vesting of restricted shares | 12,100 | 121 | - | - | - | - | - | 121 | |
| Realized and unrealized gains, net, on investment securities | - | - | - | - | - | (60,796) | - | (60,796) | |
| Stock-based compensation expense | - | - | 477,135 | - | - | - | - | 477,135 | |
| Balance at December 31, 2024 | 14,500,707 | $145,007 | $410,987,523 | 22 | $(85,188) | $ | - | $(406,803,044) | $4,244,298 |
CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
YEAR ENDED DECEMBER 31, 2023
| Common Stock Outstanding · Additional Paid-in · Treasury Stock · Accum. Other Compr. Income · Accumulated | ||||||||
|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Shares | Amount | (Loss) | Deficit | Total | |
| Balance at January 1, 2023 | 7,436,219 | $74,362 | $397,980,023 | 22 | $(85,188) | $26,494 | $(368,667,825) | $29,327,866 |
| Net loss | - | - | - | - | - | - | (19,514,977) | (19,514,977) |
| Sale of equity through equity financing facilities | 1,904,142 | 19,041 | 2,762,397 | - | - | - | - | 2,781,438 |
| Issuance of stock upon vesting of restricted shares | 59,450 | 595 | - | - | - | - | - | 595 |
| Realized and unrealized gains, net, on investment securities | - | - | - | - | - | 34,302 | - | 34,302 |
| Stock-based compensation expense | - | - | 758,418 | - | - | - | - | 758,418 |
| Balance at December 31, 2023 | 9,399,811 | $93,998 | $401,500,838 | 22 | $(85,188) | $60,796 | $(388,182,802) | $13,387,642 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.